- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Low Part D Premiums Can’t Last If Rebate Rule Finalized
The administration's rebate rule will undermine negotiations that have secured savings for seniors.
Last night, CMS announced that the average basic premium for Medicare Part D prescription drug plans will be $30.50 in 2021—among the lowest since 2013. But the administration will likely see a sharp reversal if it finalizes its “rebate rule,” which will undermine the very negotiations that secure these savings for seniors.
For decades, health insurance providers have been an enthusiastic partner of the federal government—negotiating with drug makers for lower costs for seniors and taxpayers, increasing access to much-needed medications, and achieving high levels of satisfaction among the seniors they serve. They eagerly supported CMS’ Part D Senior Savings Model, which is helping to make insulin even more affordable for enrollees. And health insurance providers continue to ensure that seniors have access to their medications throughout the coronavirus disease 2019 crisis.
As Americans’ bargaining power, we will continue to negotiate hard to make drug coverage more affordable for Americans. But the rebate rule would take us in precisely the wrong direction.
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Addressing the Bidirectional Impact of Schizophrenia and Substance Use Disorders
February 8th 2025Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, discusses the bidirectional relationship between schizophrenia and substance use disorders in an interview.
Read More
